Drug Profile
Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica
Alternative Names: AL 3810; CO-3810; E-3810 - Ethical Oncology Science; S-80881; S-80881-2Latest Information Update: 15 Jul 2022
Price :
$50
*
At a glance
- Originator Advenchen Laboratories; Shanghai Institute of Materia Medica
- Developer Bristol-Myers Squibb; Clovis Oncology; HaiHe Biopharma; Servier; Shanghai Institute of Materia Medica
- Class Acetamides; Antineoplastics; Cyclopropanes; Naphthalenes; Phenyl ethers; Quinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Small cell lung cancer
- Phase II Gynaecological cancer; Malignant thymoma; Nasopharyngeal cancer; Solid tumours
- Discontinued Breast cancer; Non-small cell lung cancer
Most Recent Events
- 03 Jun 2022 Efficacy and safety data from phase II trial in LIO-1 trial in Gynaecological cancer presented at 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 24 Apr 2022 Phase-II clinical trials in Malignant thymoma in China (unspecified route) (Haihe Biopharma pipeline, April 2022)
- 24 Apr 2022 Phase-II clinical trials in Nasopharyngeal cancer (Combination therapy) in China (unspecified route) (Haihe Biopharma pipeline, April 2022)